SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUERS PURSUANT TO RULE
13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT
OF 1934
Dated: September 30, 2002
Commission file number 0-21392
AMARIN CORPORATION PLC
(Exact name of Registrant as Specified in its Charter)
ENGLAND
(Jurisdiction of Incorporation or
organization of Issuer)
7 Curzon Street
London W1J 5HG, England
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or
Form 40-F.
[X] Form 20-F [ ] Form 40-F
Indicate by check mark whether the registrant by
furnishing the information contained in this Form is
also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
[ ] Yes [X] No
Attachment:
Material Events
(a) Amarin Corporation announces research collaboration with Cellgate Inc. to
study controlled release and targeted delivery of oral medicines.
This report on Form 6-K is hereby incorporated
by reference in the registration statement on Form F-3
(Registration Statement No. 333-12642) of Amarin
Corporation plc and in the prospectus contained therein,
and in the Registration Statement on Form F-3
(Registration No. 333-13200) of Amarin Corporation plc
and in the prospectus contained therein, and this report
on Form 6-K shall be deemed a part of each such
registration statement from the date on which this
report is filed, to the extent not superseded by
documents or reports subsequently filed.
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
AMARIN CORPORATION PLC
By:/s/Richard A B Stewart
Richard A B Stewart
Chief Executive Officer
Date: September 30, 2002
Index to
Exhibits
Exhibit Item Sequentially Numbered Page
(a) Material Event description- 4
Amarin Corporation announces research
collaboration with Cellgate Inc. to
study controlled release and targeted
delivery of oral medicines
Exhibit
(a)
Contacts:
Rick Stewart
Chief Executive Officer
Amarin Corporation plc
Phone: +44 (0) 207 907 2440
Email: rick.stewart@amarincorp.com
Amarin Corporation announces research collaboration with Cellgate Inc. to study
controlled release and targeted delivery of oral medicines
LONDON, United Kingdom, September 30, 2002 -- Amarin Corporation plc
(Nasdaq: AMRN) today announced that its Swedish subsidiary, Amarin Development
AB, has entered into a research collaboration with CellGate Inc. to assess the
feasibility of improving Amarin's targeted and controlled delivery of oral
pharmaceutical products by combining Amarin's proprietary drug delivery
technology with CellGate's proprietary molecular transporter technology.
During the initial phase of the collaboration, in which each party will be
responsible for individual costs, CellGate's technology will be used to develop
drug transporter conjugates of two currently undisclosed drug substances.
These drug conjugates will then be incorporated into Amarin's Diffusion
Controlled Vesicle (DCV) controlled-release technology.
The scope of the research will initially focus on drugs that are difficult
to deliver orally due to their low or local absorption into the bloodstream.
The combination of the two technologies could be applied to new compounds, as
well as currently marketed drugs, that are not available in extended-release
formulations due to absorption issues that negatively impact bioavailability.
If successful, the new combination technology could potentially improve the
extended release profile of these drugs. Further details of the agreement were
not disclosed.
"Amarin is committed to enhancing the value of our technology platforms
through innovative research partnerships and collaborations," said Rick
Stewart, chief executive officer of Amarin Corporation. "This new combination
technology has the potential to both improve the quality of controlled release
drugs on the market and broaden the range of drug molecules that can be
effectively delivered orally. Most importantly, we believe that this
combination has the potential to significantly benefit our patients and
customers, and further the advancement of our internal drug development efforts
in the key areas of neurology and pain management."
Amarin's DCV system is used for the controlled release of substances for
periods up to 24 hours. The patented technology consists of a tablet core,
incorporating the active ingredient, surrounded by a water-insoluble membrane
containing minute particles of water-soluble material. The soluble particles
dissolve when the tablet is ingested, resulting in a macro-porous film
structure through which drug is released at a steady rate. Principal licensees
for the technology include Pharmacia, Sanofi-Synthelabo and Tanabe Seiyaku.
Over three billion tablets incorporating the DCV technology have been
manufactured and used effectively by patients in more than thirty countries.
About Amarin
Amarin Corporation plc is a specialty pharmaceutical company focused on
neurology and pain management. The Company plans to become a leader in these
therapeutic categories by providing innovative products and solutions that
address significant unmet medical needs. For press releases and other Company
information, visit our website at www.amarincorp.com.
Amarin Development AB, based in Malmo, Sweden, is a wholly owned
subsidiary of Amarin Corporation plc. It is dedicated to the research and
development of advanced controlled release and site-specific technology
solutions to create improved outcome formulations of both new and existing
drugs. Additional information is available at www.amarindev.com.
About CellGate
CellGate Inc. is an emerging specialty pharmaceutical company developing
novel medicines by chemically combining proprietary transporter molecules with
existing drugs in order to improve therapeutic value and drug performance. The
company's proprietary transporter technology enhances drug performance by
allowing medicines to penetrate through biological barriers for more efficient
cell entry. CellGate's unique technologies are applicable to a broad range of
molecules and may be tailored to suit diverse therapeutic indications.
Initially, CellGate is focusing its efforts in the areas of dermatology and
oncology, with a lead drug candidate for psoriasis, PsorBan (r) currently in
early clinical studies. The company is also pursuing new therapeutics in other
areas for development with partners. Founded in 1998 and headquartered in
Sunnyvale, California, CellGate is privately held. For more information about
the company, please refer to the company's website at www.cellgateinc.com.
Statements in this press release that are not historical facts are forward-
looking statements that involve risks and uncertainties which may cause the
Company's actual results in future periods to be materially different from any
performance suggested herein. Such risks and uncertainties include, without
limitation, risks associated with the inherent uncertainty of pharmaceutical
research, product development and commercialisation, the impact of competitive
products and patents, as well as other risks and uncertainties detailed from
time to time in periodic reports. For more information, please refer to Amarin
Corporation's Annual Report for 2001 on Form 20-F and its Form 6-Ks as filed
with the U.S. Securities and Exchange Commission. The Company assumes no
obligation to update information on its expectations.